XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.2
License agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Feb. 28, 2018
USD ($)
Jan. 08, 2018
$ / shares
License agreements                
Long term investments   $ 222,810   $ 222,810   $ 133,657    
Research and development expense   438,109 $ 281,336 1,809,997 $ 841,244      
Unrealized gain (loss) on long term investments   (13,207) 2,339 10,935 18,703      
Syros Pharmaceuticals, Inc.                
License agreements                
Number of program targets | item 7              
Upfront payment under license agreement $ 10,000              
Long term investments   $ 8,300   $ 8,300   $ 6,500    
Ownership percentage (as a percent)   2.00%   2.00%        
Unrealized gain (loss) on long term investments   $ (1,700) $ 1,100 $ 1,800 $ 4,600      
Syros Pharmaceuticals, Inc. | Stock purchase agreement                
License agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8              
Purchase price of common stock $ 10,000              
Per share price | $ / shares $ 12.61             $ 9.77
Lock-up period 12 months              
Discount for lack of marketability $ 100              
Fair value of shares on the issuance date 7,600              
Long term investments 7,600              
Research and development expense $ 2,400              
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement                
License agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1              
Purchase price of common stock $ 1,400              
Per share price | $ / shares $ 9.55              
Long term investments             $ 1,400  
Syros Pharmaceuticals, Inc. | Maximum                
License agreements                
Target selection and option exercise fee payment $ 54,000              
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum                
License agreements                
Additional milestone payments under the license agreement 50,000              
Syros Pharmaceuticals, Inc. | Sales and Commercial Milestones | Maximum                
License agreements                
Additional milestone payments under the license agreement $ 65,000